|
Musculoskeletal Health: An Ecological Study Assessing
Disease Burden and Research Funding
Lancet Reg Health Am 2024 (Jan 8): 29: 100661 ~ FULL TEXT
Before undertaking this study, we conducted an extensive literature review to identify existing evidence related to the relationship between disease burden and research funding, particularly focusing on the National Institutes of Health (NIH) and the Global Burden of Disease (GBD) data.
Disease Burden is measured by 3 characteristics:
• Disability-Adjusted Life Years (DALYs),
• Years Lived with Disability (YLDs)
,
• Years of Life Lost (YLLs)
The goal was to gather insights into the existing body of knowledge surrounding disease burden and research funding disparities to inform our ecological study design and analysis methodology.
Implications of all the available evidence
Global health morbidity has shifted in recent decades from
communicable, maternal, neonatal, and nutritional (CMNN) diseases to
non-communicable diseases (NCDs). [1]
As death rates have declined, non-fatal injuries and NCDs have become a significant concern for health systems.
When rerviewing the 2019 disease burden (measured in DALYs) and 2021
NIH funding levels, 23.4% of funding variation were driven by DALYs.
A DALY (Disability-Adjusted Life Year) is a measure of health burden, including both reduction in life expectancy and diminished quality of life. More specifically, the DALY burden for a particular condition is the sum of YLL (years of life lost due to premature mortality) and YLD (years lost to disability).
However, in the 2021 NIH funding, all musculoskeletal diseases were underfunded, compared to their societal/economic burden, with low back pain receiving the least relative funding, at $496.4 million less funding than was predicted.
Predicted funding levels were derived to assess the adequacy of funding for various diseases. Subsequently, the ratios of actual to predicted 2021 NIH funding for diseases characterized as underfunded (where the ratio <1) were determined. Musculoskeletal diseases were underfunded relative to their disease burden, with neck pain receiving the least funding at 0.83% of the predicted amount.
Low back pain, osteoarthritis, and rheumatoid arthritis were underfunded at 13.88%, 35.08%, and 66.26% of predicted amounts, respectively. To be commensurate with their actual total burden, funding for neck pain, low back pain, and osteoarthritis would need to increase 120–fold, 7–fold, and 3–fold, respectively.
U.S. burden of disease
We compared prevalence, DALYs, and YLDs among 22 disease classifications. In 2019, musculoskeletal diseases were the leading cause of disability years, contributing 25.71% of total YLDs.
Musculoskeletal diseases were also the third leading cause of DALYs, contributing 12.50% of the total, and were the third most prevalent disease, with 40.96% prevalence
Burden of disease in DALYs
From 1990 to 2019, the CMNN disease burden decreased in the U.S. and globally while the NCD burden increased. However, at the same time, the musculoskeletal disease burden steadily increased.
Musculoskeletal diseases accounted for approximately 14 million DALYs, making them the third leading cause of U.S. DALYs in 2019. There was also a 5.13% increase in the proportion of total DALYs from 2009 to 2019.
Low back pain was the third leading cause of DALYs, with an 8.49% increase from 2009 to 2019.
There was a significant increase in the disease burden of neck pain, with an 86.3% increase in the DALY rate and a 99.5% increase in total DALYs.
Research funding for musculoskeletal diseases is disproportionately low compared to most other diseases. Total 2018–2022 funding for cancer ($34.9 billion) was almost double the funding for ALL musculoskeletal-related conditions combined ($18.5 billion), amd MSK condotions include 20 different categories to fund, such as osteoarthritis, injuries, and pain research.
Back pain ($416 million) and neck pain ($9 million) were among the least funded,
ranked at #201 and #307, out of 309 categories.
Musculoskeletal disease burden and NIH funding
We compared the proportion of total YLDs and DALYs to NIH institute-specific funding. For disease burden, we selected 20 categories representing 86.10% of total DALYs and 86.59% of total YLDs in 2019. In addition, we selected 12 of the 26 NIH-funded institutes/centers, which comprised 68.20% of the total NIH-allocated funding dollars in 2019.
In 2019, musculoskeletal and skin diseases comprised 14.47% and 29.60% of total DALYs and YLDs, respectively. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) received only 1.54% of the NIH funding. NIAMS had the lowest ratio of NIH funding for Disease burden (DALY or YLD).
U.S. healthcare spending is rising, accounting for 18% of the country’s economy. [29] A study from 2020 found that low back and neck pain, other musculoskeletal disorders, and osteoarthritis are among the top conditions with the highest healthcare spending, totalling $344.3 billion. [8] The annual cost of musculoskeletal diseases is estimated at $980 billion or 5.8% of the U.S. gross domestic product. [30]
These diseases also lead to indirect costs such as lost wages, commonly affecting individuals during their peak earning years. In addition, musculoskeletal diseases are the leading cause of disability, responsible for one-third of worker’s compensation claims [31] and over 200 million workdays lost. [30]
It is time to assign accountants to review this information so a compelling presentation can be submitted to NIH to address these imbalances.
|